<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002806</url>
  </required_header>
  <id_info>
    <org_study_id>1011003552</org_study_id>
    <nct_id>NCT02002806</nct_id>
  </id_info>
  <brief_title>Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control</brief_title>
  <official_title>A Randomized Controlled Trial of Intraoperative Chemical Splanchnicectomy for Patients With Resected Pancreatobiliary Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study of surgery plus chemical nerve block versus surgery plus placebo&#xD;
      for pain control in subjects with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thi is a study of pain control in subjects undergoing surgery for pancreatic or bile duct&#xD;
      cancer.&#xD;
&#xD;
      Subjects undergoing surgery will be randomized to surgery plus celiac plexus neurolysis with&#xD;
      ethanol injection versus surgery plus placebo injection. Subjects will be followed every&#xD;
      three months for survivorship or death to assess pain, quality of life measures, and narcotic&#xD;
      pain control usage. The primary endpoint of pain control will be determined at one year post&#xD;
      surgery. Subjects are not required to undergo any additional diagnostic testing procedures&#xD;
      that are not part of their routine follow-up care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Control</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-specific, recurrence-free survival</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Alcohol Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celiac plexus neurolysis by alcohol injection One time administration during surgery 20 ml of alcohol injection on each side of aorta at level of celiac axis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Celiac plexus injection - placebo injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alcohol Injection</intervention_name>
    <description>Celiac plexus neurolysis by alcohol injection</description>
    <arm_group_label>Alcohol Injection</arm_group_label>
    <other_name>Ethanol Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <arm_group_label>Placebo Injection</arm_group_label>
    <other_name>Normal saline injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        This study will be offered to all patients scheduled to undergo open or laparoscopic&#xD;
        operative resection of a presumed pancreatic (any location; i.e., head, body, or tail) or&#xD;
        distal biliary tract cancer.&#xD;
&#xD;
          -  Physiologic suitability for major abdominal surgery&#xD;
&#xD;
          -  Aged 18 years and older&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Ability to understand and comply with study guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Previous, preoperative celiac nerve block&#xD;
&#xD;
          -  Neoadjuvant chemotherapy or radiation therapy&#xD;
&#xD;
          -  Incomplete tumor resection (R2 resection, grossly positive resection margin)&#xD;
&#xD;
          -  Presumed ampullary or duodenal cancer based on preoperative work-up or intraoperative&#xD;
             findings&#xD;
&#xD;
          -  Benign tumors, neuroendocrine tumors, soft tissue tumors based on preoperative work-up&#xD;
             or intraoperative findings&#xD;
&#xD;
          -  Known metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael G House, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University, Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Michael G. House</investigator_full_name>
    <investigator_title>Associate Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

